Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 6/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.50 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.48 |
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29881695 | 0.86 | OPRD1 (0.53) | OPRD1F2APLNRNTSR1 | |
| SCHEMBL31376412 | 0.85 | RAMP3 (0.54) | — | |
| SCHEMBL30432612 | 0.83 | RAMP3 (0.56) | — | |
| SCHEMBL30455559 | 0.83 | RAMP3 (0.61) | — | |
| SCHEMBL30431713 | 0.82 | NPY2R (0.52) | — | |
| SCHEMBL30390834 | 0.80 | RAMP3 (0.63) | — | |
| SCHEMBL30847581 | 0.80 | RAMP3 (0.60) | — | |
| SCHEMBL30930173 | 0.79 | NPY2R (0.53) | — | |
| SCHEMBL30457049 | 0.79 | OPRM1 (0.49) | OPRD1 | |
| SCHEMBL30930139 | 0.79 | CALCR (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313116-A1 | COMPOSITIONS AND ARTICLES COMPRISING AN ADNF POLYPEPTIDE | Ramot at Tel-Aviv University Ltd. (IL) | 2024-02-07 | — | — | EP | disclosed |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | disclosed |
| WO-2022201166-A1 | COMPOSITIONS AND ARTICLES COMPRISING AN ADNF POLYPEPTIDE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-09-29 | — | — | WO | disclosed |
| US-11407755-B2 | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2022-08-09 | — | — | US | disclosed |
| US-11278525-B1 | Further molecules, compositions and methods for modulation of SIRT6 | SirTLab Corporation (IL) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278525-B1 | Further molecules, compositions and methods for modulation of SIRT6 | SIRT6, SIRT1, SIRT2 | OPRD1 4518/4885F2 4614/4885OPRL1 4488/4885 |
| US-11407755-B2 | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | OPRD1 4170/4885F2 2404/4885OPRL1 4342/4885 |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | MKI67, CCNB1, CCNB2 | OPRD1 4170/4885F2 2404/4885OPRL1 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.